Oruka's ORKA-001 achieves complete skin clearance in 61% of high-dose patients in Phase 2b psoriasis trial
ORKA•Oruka Therapeutics said ORKA-001 achieved complete skin clearance in 61% of high-dose patients in its Phase 2b psoriasis trial. Phase 3 trials are planned for the first half of 2027, pending regulatory discussions.
1. Phase 2b results
Oruka Therapeutics announced positive Phase 2b EVERLAST-B results for ORKA-001 in moderate-to-severe plaque psoriasis. The highest dose produced complete skin clearance in 61% of patients, with results consistent with the earlier EVERLAST-A trial. The high-dose group had no serious treatment-emergent adverse events.
2. Next trial milestones
Oruka plans Phase 3 trials in the first half of 2027, pending regulatory discussions. Longer-term results from EVERLAST-A are expected in December 2026, followed by EVERLAST-B results in the second half of 2027.
